Immunome IMNM Charge For Purchase Of In Process Research And Development Assets Including Upon Achievement Of Milestones
Charge For Purchase Of In Process Research And Development Assets Including Upon Achievement Of Milestones at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept imnm:ChargeForPurchaseOfInProcessResearchAndDevelopmentAssetsIncludingUponAchievementOfMilestones.
The official record: Immunome’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's charge for purchase of in process research and development assets including upon achievement of milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's charge for purchase of in process research and development assets including upon achievement of milestones?
- Immunome (IMNM) reported charge for purchase of in process research and development assets including upon achievement of milestones of $2.5M in Q4 2025.
- How has Immunome's charge for purchase of in process research and development assets including upon achievement of milestones changed year-over-year?
- Immunome's charge for purchase of in process research and development assets including upon achievement of milestones decreased by 93.4% year-over-year, from $38.09M to $2.5M.
- What does charge for purchase of in process research and development assets including upon achievement of milestones mean?
- This represents the non-cash expense recognized when acquiring in-process research and development assets, often triggered by the achievement of specific development milestones. It reflects the accounting treatment of intangible assets that have not yet reached technological feasibility. Monitoring this helps investors assess the cost of inorganic growth and the impact of milestone-based R&D strategies on reported earnings.